Document Type : Original Article
Authors
- Amir Janadliean 1
- Shokrollah Salmanzadeh 1
- Roohangiz Nashibi 1
- Seyed Mohammad Alavi 1
- Sasan Moogahi 1
- Saied Bitaraf 2
1 Infectious and Tropical Diseases Research Center, Health Research Institute, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Clinical Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Abstract
Background: There is still no specific treatment strategy for COVID-19 other than supportive management. The potential biological benefits of ozone therapy include reduced tissue hypoxia, decreased hypercoagulability, modulated immune function by inhibiting inflammatory mediators, improved phagocytic function, and impaired viral replication. This study aimed to evaluate the effect of intravenous ozonated normal saline on patients with severe COVID-19 disease.
Methods: In this study, a single centralized randomized clinical trial was conducted on 80 hospitalized patients with severe COVID-19. The patients were selected by random allocation method and divided into two groups A and B. In group A (control group), patients were given standard drug treatment, and in group B (intervention group), patients received ozonated normal saline in addition to the standard drug treatment. In the intervention group, 400 mL of normal saline was weighed by 40 μg/ kg of body weight and was injected into patients within 15 to 30 minutes (80 to 120 drops per minute). This process was done daily every morning for a week. Primary and secondary outcomes of the disease included changes in the following items: length of hospital stay, inflammatory markers including C-reactive protein (CRP), clinical recovery, arterial blood oxygen status, improvement of blood disorders such as leukopenia and leukocytosis, duration of ventilator attachment, and rapid clearance of lung lesions on CT scans. The need for intensive care unit (ICU) hospitalization, the length of ICU stay, and the mortality rate in patients of the two groups was compared.
Results: According to the results of the initial outcome variable analysis, the probability of discharge of patients who received the normal ozonated saline intervention was 33% higher than patients who did not receive this intervention; however, this relationship was not statistically significant (HR = 0.67, 95%, CI = 0.42-1.06, P value = 0.089). The chance of ICU hospitalization in patients of the intervention group was three times more than that of the comparison group, but this relationship was not significant (odds ratio = 4.4 95% CI = 1.32-14.50, P value = 0.016). The use of ozonated normal saline was found to increase the risk of death by 1.5 times but this relationship was not statistically significant (odds ratio=1.5, 95% CI=.24-9.75, P value=0.646). Ozonated normal saline had a significant effect on changes in respiration rate (in the intervention group the number of breaths was decreased) and the erythrocyte sedimentation rate (in the intervention group the erythrocyte sedimentation rate was increased); however, it had no significant effect on other indicators.
Conclusion: The present study showed that ozone therapy in hospitalized patients with severe COVID-19 could help improve some primary and secondary outcomes of the disease. Governments and health policymakers should make ozone therapy an available care service so that the need for advanced treatment facilities decreases; consequently, this measure may improve patient safety, prevent lung tissue destruction, and control cytokine storms in patients. Additionally, health decision-makers need to aim for the effective clinical improvement of patients, especially severe ones, and the reduction of their mortality. However, further large-scale multicenter studies with larger sample sizes considering drug side effects and other variables influencing the clinical course of COVID-19 can provide more information on the effectiveness and importance of ozone therapy.
Highlights
Shokrollah Salmanzadeh(Google scholar)(Pubmed)
Roohangiz Nashibi(Google scholar)(Pubmed)
Sasan Moogahi(Pubmed)
Saeid Bitaraf(Google scholar)(Pubmed)
Keywords
- Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update. Cureus. 2020;12(3):e7423. doi: 10.7759/cureus.7423.
- Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924.
- Ahmad T, Rodriguez-Morales AJ. Emergence of COVID-19 (formerly 2019-novel coronavirus): a new threat from China. Revista Panamericana de Enfermedades Infecciosas. 2019;2(2):37-8.
- Zhou Z, Qiu Y, Ge X. The taxonomy, host range and pathogenicity of coronaviruses and other viruses in the Nidovirales order. Anim Dis. 2021;1(1):5. doi: 10.1186/ s44149-021-00005-9.
- Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J. 2020;39(5):355-68. doi: 10.1097/inf.0000000000002660.
- Zhang X, Cai H, Hu J, Lian J, Gu J, Zhang S, et al. Epidemiological, clinical characteristics of cases of SARSCoV-2 infection with abnormal imaging findings. Int J Infect Dis. 2020;94:81-7. doi: 10.1016/j.ijid.2020.03.040.
- Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93(1):250-6. doi: 10.1002/jmv.26232.
- Huang Q, Wu X, Zheng X, Luo S, Xu S, Weng J. Targeting inflammation and cytokine storm in COVID-19. Pharmacol Res. 2020;159:105051. doi: 10.1016/j.phrs.2020.105051.
- Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409-24. doi: 10.1038/s41579-021-00573-0.
- Kulus J, Kulus M, Stefańska K, Sobolewski J, PiotrowskaKempisty H, Mozdziak P, et al. SARS-CoV-2 genetic variability and non-specific immunity associated with the use of different BCG strains-a molecular and clinical approach. Vaccines (Basel). 2021;9(6):639. doi: 10.3390/vaccines9060639.
- Mobinizadeh MR, Arab-Zozani M. Safety and effectiveness of favipiravir for novel coronavirus (COVID-19): a rapid review of available evidence. Health Technology Assessment in Action. 2020;4(1):e5862. doi: 10.18502/htaa.v4i1.5862.
- Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020;53(3):436-43. doi: 10.1016/j.jmii.2020.03.034.
- Cattel F, Giordano S, Bertiond C, Lupia T, Corcione S, Scaldaferri M, et al. Ozone therapy in COVID-19: a narrative review. Virus Res. 2021;291:198207. doi: 10.1016/j. virusres.2020.198207.
- Elvis AM, Ekta JS. Ozone therapy: a clinical review. J Nat Sci Biol Med. 2011;2(1):66-70. doi: 10.4103/0976-9668.82319.
- Remondino M, Valdenassi L. Different uses of ozone: environmental and corporate sustainability. Literature review and case study. Sustainability. 2018;10(12):4783. doi: 10.3390/su10124783.
- Wang T, Xiang Q, Bian J. Promising gas therapies for severe COVID-19. J Intensive Med. 2021;1(2):99-102. doi: 10.1016/j. jointm.2021.05.001.
- Bocci V. The clinical application of ozonetherapy. In: Bocci V, ed. OZONE: A New Medical Drug. Dordrecht: Springer; 2011. p. 97-232. doi: 10.1007/978-90-481-9234-2_9.
- Juchniewicz H, Lubkowska A. Oxygen-ozone (O2-O3) therapy in peripheral arterial disease (PAD): a review study. Ther Clin Risk Manag. 2020;16:579-94. doi: 10.2147/tcrm. s255247.
- Araimo F, Imperiale C, Tordiglione P, Ceccarelli G, Borrazzo C, Alessandri F, et al. Ozone as adjuvant support in the treatment of COVID-19: a preliminary report of probiozovid trial. J Med Virol. 2021;93(4):2210-20. doi: 10.1002/jmv.26636.
- Hafeez A, Ahmad S, Siddqui SA, Ahmad M, Mishra S. A review of COVID-19 (coronavirus disease-2019) diagnosis, treatments and prevention. Eurasian J Med Oncol. 2020;4(2):116-25. doi: 10.14744/ejmo.2020.90853.
- Çolak Ş, Genç Yavuz B, Yavuz M, Özçelik B, Öner M, Özgültekin A, et al. Effectiveness of ozone therapy in addition to conventional treatment on mortality in patients with COVID-19. Int J Clin Pract. 2021;75(8):e14321. doi: 10.1111/ ijcp.14321.
- Shah M, Captain J, Vaidya V, Kulkarni A, Valsangkar K, Nair PMK, et al. Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: a phase 1/11 randomized control trial (SEOT study). Int Immunopharmacol. 2021;91:107301. doi: 10.1016/j.intimp.2020.107301.
- Hernández A, Viñals M, Pablos A, Vilás F, Papadakos PJ, Wijeysundera DN, et al. Ozone therapy for patients with COVID-19 pneumonia: preliminary report of a prospective case-control study. Int Immunopharmacol. 2021;90:107261. doi: 10.1016/j.intimp.2020.107261.
- Hernández A, Viñals M, Isidoro T, Vilás F. Potential role of oxygen-ozone therapy in treatment of COVID-19 pneumonia. Am J Case Rep. 2020;21:e925849. doi: 10.12659/ajcr.925849.
- Ricevuti G, Franzini M, Valdenassi L. Oxygen-ozone immunoceutical therapy in COVID-19 outbreak: facts and figures. Ozone Ther. 2020;5(1):9014. doi: 10.4081/ ozone.2020.9014.
- Blanco A, Ojembarrena FB, Clavo B, Negro C. Ozone potential to fight against SAR-COV-2 pandemic: facts and research needs. Environ Sci Pollut Res Int. 2021;28(13):16517-31. doi: 10.1007/s11356-020-12036-9.
- Al-Hegelan M, Tighe RM, Castillo C, Hollingsworth JW. Ambient ozone and pulmonary innate immunity. Immunol Res. 2011;49(1-3):173-91. doi: 10.1007/s12026-010-8180-z.
- Fernández-Cuadros ME, Albaladejo-Florín MJ, Peña-Lora D, Álava-Rabasa S, Pérez-Moro OS. Ozone (O3) and SARS-CoV-2: physiological bases and their therapeutic possibilities according to COVID-19 evolutionary stage. SN Compr Clin Med. 2020;2(8):1094-102. doi: 10.1007/s42399-020-00328-7.
- Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24(1):422. doi: 10.1186/s13054-020-03120-0.
- Bousquet J, Cristol JP, Czarlewski W, Anto JM, Martineau A, Haahtela T, et al. Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies. Clin Transl Allergy. 2020;10(1):58. doi: 10.1186/s13601-020-00362-7.
- Eren E, Saribek F, Kalayci Z, Yilmaz N. How to cripple SARSCoV-2 virus with ozone treatment thiol groups in viruses and SARS-CoV-2. 2020. doi: 10.13140/rg.2.2.30726.40004.
- Ranaldi GT, Villani ER, Franza L, Motola G. Ozonetherapy: a multirole weapon, topical pathway against SARS-CoV-2. 2020. https://osf.io/preprints/frenxiv/n2dup/download.
)